Publications

Publication List – Professor Jürgen Götz (as of May 10, 2015)

 

Total impact factor: 938; 10203 citations (Google Scholar), 5947 citations since 2010;

H-factor: 50

ResearcherID C-2448-2014

 

(a) Peer-reviewed articles

 

  1. Cho KWY, Götz J, Fritz A, Hardwicke J, DeRobertis, EM (1988) Differential utilization of the same reading frame in a Xenopus homeobox gene encodes two related proteins sharing the same DNA-binding specificity. EMBO J. 7: 139-149

Impact factor: 10.748 (115 cit.)

 

  1. Götz J, Eibel H, Köhler G (1990) Non-tolerance and differential susceptibility to diabetes in transgenic mice expressing major histocompatibility class II genes on pancreatic beta cells. Eur. J. Imm. 20: 1677-1683

Impact factor: 4.518 (21 cit.)

 

  1. Hebert JM, Rosenquist T, Götz J, Martin GR (1994) FGF5 as a regulator of the hair growth cycle: Evidence from targeted and spontaneous mutations. Cell 78: 1017-1025

Impact factor: 33.116 (467 cit.)

 

  1. Götz J, Probst A, Spillantini MG, Schäfer T, Jakes R, Bürki K, Goedert M (1995) Somatodendritic localisation and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. 14: 1304-1313

Impact factor: 10.748 (355 cit.)

  1. Goedert M, Jakes R, Spillantini MG, Crowther RA, Cohen P, Vanmechelen E, Probst A, Götz J, Bürki K (1995) Tau protein in Alzheimer’s disease. Biochem. Soc. Transact. 23: 80-85

Impact factor: 3.238 (28 cit.)

  1. Goedert M, Spillantini MG, Jakes R, Crowther RA, Vanmechelen E, Probst A, Götz J, Bürki K, Cohen P (1995) Molecular dissection of the paired helical filament. Neurobiology of Aging 16: 325-334

Impact factor: 4.853 (87 cit.)

 

  1. Li ZW, Stark G, Götz J, Rülicke T, Müller U, Weissmann C (1996) Generation of mice with a 200-kb amyloid precursor protein gene deletion by Cre recombinase-mediated site-specific recombinatiton in embryonic stem cells. PNAS 93: 6158-6162

Impact factor: 9.809 137 cit.)

 

  1. Shmerling D, Hegyi I, Fischer M, Blättler T, Brandner T, Götz J, Rülicke T, Flechsig E, Cozzio A, von Mering C, Hangartner C, Aguzzi A, Weissmann C (1998) Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 93: 203-214

Impact factor: 33.116 (472 cit.)

  1. Götz J, Probst A, Ehler E, Hemmings B, Kues W (1998) Delayed embryonic lethality in mice lacking protein phosphatase 2A catalytic subunit Cα. PNAS 95: 12370-12375

Impact factor: 9.809 (195 cit.)

 

  1. Götz J, Kues W (1999) The role of protein phosphatase 2A catalytic subunit Cα in embryogenesis: Evidence from sequence analysis and localization studies. Biol. Chem. 380: 1117-1120 [cover image]

Impact factor: 2.689 (17 cit.)

 

  1. Götz J, Probst A, Mistl C, Nitsch RM, Ehler E (2000) Distinct role of protein phosphatase 2A subunit Cα in the regulation of E-cadherin and β-catenin during development. Mech. Dev. 93: 83-93

Impact factor: 2.238 (70 cit.)

  1. Götz J, Barmettler R, Ferrari A, Goedert M, Probst A, Nitsch RM (2000) Molecular basis of dementia: In vivo analysis of wild-type and FTDP-17 tau mutant mice. Ann. N.Y.Acad. Sci. 920: 126-133

Impact factor: 4.039 (22 cit.)

  1. Probst A, Götz J, Wiederhold KH, Tolnay M, Mistl C, Jaton AL, Hong M, Ishihara T, Lee VM-Y, Trojanowski JQ, Jakes R, Crowther RA, Spillantini MG, Bürki K, Goedert M (2000) Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol. 99: 469-481

Impact factor: 9.777 (288 cit.)

  1. Ferrari A, Ehler E, Nitsch RM, Götz J (2000) Immature human NT2 cells grafted into mouse brain differentiate into neuronal and glial cell types. FEBS Letters 486: 121-125

Impact factor: 3.341 (66 cit.)

  1. Götz J, Tolnay M, Barmettler R, Ferrari A, Bürki K, Goedert M, Probst A, Nitsch RM (2000) Human tau transgenic mice. Towards an animal model for neuro- and glialfibrillary lesion formation. Adv. Exp. Med. Biol. 487: 71-83

Impact factor: 2.012 (14 cit.)

 

  1. Götz J (2001) Tau and transgenic animal models, Brain Res. Rev. 35: 266-286

Impact factor: 5.930 (157 cit.)

  1. Götz J, Tolnay M, Barmettler R, Chen F, Probst A, Nitsch RM (2001) Oligodendroglial tau filament formation in transgenic mice expressing G272V tau, Eur. J. Neurosci. 13: 2131-2140

Impact factor: 3.669 (100 cit.)

  1. Götz J, Nitsch RM (2001) Compartmentalized tau hyperphosphorylation and increased levels of kinases in transgenic mice, Neuroreport 12: 2007-2016

Impact factor: 1.644 (42 cit.)

  1. Götz J, Chen F, Barmettler R, Nitsch RM (2001) Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 276: 529-534

Impact factor: 4.600 (367 cit.)

  1. Götz J (2001) Tau be or not tau be – Tauopathien und transgene Tiermodelle, Neuroforum, 3/01: 93-101

Impact factor: N.A.

  1. Götz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta42 fibrils, Science 293: 1491-1495 [discussed in a Perspectives article: Lee VM-Y (2001) Tauists and βaptists united – Well almost!, Science 293: 1446-1447] [selected for Faculty of 1000 Biology]

Impact factor: 31.477 (1074 cit.)

  1. Götz J, Chen F, Nitsch RM (2001) Interactions of beta-amyloid with the formation of neurofibrillary tangles in transgenic mice. In: Mapping the Progress of Alzheimer’s and Parkinson’s Disease (editors: Y.Mizuno, A. Fisher, I. Hanin; Kluver Academic/Plenum Publishers) Adv. in Beh. Biol. 51: 139-144

Impact factor: N.A.

  1. Kins S, Crameri A, Evans DRH, Hemmings BA, Nitsch RM, Götz J (2001) Reduced PP2A activity induces abnormal phosphorylation and compartmentalization of tau in transgenic mice, J. Biol. Chem. 276: 38193-38200

Impact factor: 4.600 (183 cit.)

 

  1. Kurosinski P, Götz J (2002) Glial cells under physiologic and pathologic conditions (Basic science seminar in neurology), Arch. Neurol. 59: 1524-1528

Impact factor: 7.008 (70 cit.)

  1. Schmidt K, Kins S, Schild A, Nitsch RM, Hemmings B, Götz J (2002) Diversity, developmental regulation and distribution of murine PR55/B subunits of protein phosphatase 2A, Eur. J. Neurosci. 16: 2039-2048

Impact factor: 3.669 (48 cit.)

  1. Kurosinski P, Guggisberg M, Götz J (2002) Alzheimer’s disease and Parkinson’s disease – overlapping or synergistic pathologies? (Research News), Trends Mol. Med. 8: 3-5

Impact factor: 10.110 (46 cit.)

 

  1. Götz J, Schild A (2003) Protein phosphatases: Transgenic and knockout models of PP2A, Methods Enzymol. 366: 390-403

Impact factor: 2.194 (29 cit.)

  1. Flechsig E, Hegyi I, Leimeroth R, Zuniga A, Rossi D, Cozzio A, Schwarz P, Rülicke R, Götz J, Aguzzi A, Weissmann C (2003) Expression of truncated PrP targeted to Purkinje cells of PrP knockout mice causes Purkinje cell death and ataxia, EMBO J. 22: 3095-3101

Impact factor: 10.748 (74 cit.)

  1. Streffer JR, Papassotiropoulos A, Kurosinski P, Signorell A, Wollmer MA, Tsolaki M, Iakovidou V, Hörndli F, Bosset J, Götz J, Nitsch RM, Hock C (2003) Saitohin gene is not associated with Alzheimer’s disease, J. Neurol. Neurosur. Ps. 74: 362-363

Impact factor: 5.580 (19 cit.)

  1. Kins S, Kurosinski P, Nitsch RM, Götz J (2003) Activation of the ERK and JNK signaling pathways caused by neuron specific inhibition of PP2A in transgenic mice, Am. J. Pathol. 163: 833-843

Impact factor: 4.602 (129 cit.)

  1. Ferrari A, Hoerndli F, Baechi T, Nitsch RM, Götz J (2003) β-Amyloid induces PHF-like tau filaments in tissue culture, J. Biol. Chem. 278, 40162-40168

Impact factor: 4.600 (151 cit.)

 

  1. Martens E, Stevens I, Janssens V, Vermeesch J, Götz J, Goris J, van Hoof C (2004) Genomic organization, chromosomal localization, tissue distribution and developmental regulation of the PR61/B’ regulatory subunits of Protein Phosphatase 2A in mice, J. Mol. Biol. 336: 971-986

Impact factor: 3.959 (36 cit.)

  1. Pennanen L, Welzl H, D’Adamo P, Nitsch RM, Götz J (2004) Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice, Neurobiol. Dis. 15: 500-509

Impact factor: 5.202 (71 cit.)

  1. Götz J, Streffer JR, David D, Schild A, Hoerndli F, Pennanen L, Kurosinski P, Chen F (2004) Transgenic animal models of Alzheimer’s disease and related disorders: Histopathology, behavior and therapy, Mol. Psychiatr. 9: 664-683 [cover image][recommended by AlzForum]: A recent review published in Molecular Psychiatry (2004), for example, has been commented by Dr. Rachael Neve, an Alzheimer Research Forum (ARF) Adviser, as follows: “Want a summary of the main findings obtained from transgenic models of Alzheimer’s disease? This is the review to go. I like it because it’s neither too superficial nor too detailed (in which case you lose the forest for the trees). It’s also very well written and well organized: because of its good organization, you can use it as a reference to look up specific aspects of this sub-field in which you are interested. Definitely a must-read.”

Impact factor: 15.147 (216 cit.)

  1. Rauer M, Götz J, Schuppli D, Staeheli P, Hausmann J (2004) Transgenic mice expressing the nucleoprotein of Borna disease virus (BDV) in neurons and astrocytes have decreased susceptibility to homotypic infection and BDV-induced disease, J. Virol. 78: 3621-3632.

Impact factor: 4.648 (22 cit.)

  1. Chen F, David D, Ferrari A, Götz J (2004) Posttranslational modifications of tau – Role in human tauopathies and modelling in transgenic animal models, Current Drug Targets 5: 503-515

Impact factor: 3.597 (85 cit.)

  1. Chen F, Wollmer A, Hoerndli F, Münch G, Kuhla B, Rogaev EI, Tsolaki M, Papassotiropoulos A, Götz J (2004) Role for glyoxalase I in Alzheimer’s disease, PNAS 101: 7687-7692

Impact factor: 9.809 (133 cit.)

  1. Götz J, Schild A, Hoerndli F, Pennanen L (2004) Amyloid-induced neurofibrillary tangle formation in Alzheimer’s disease: insight from transgenic mouse and tissue-culture models, Int. J. Dev. Neurosci. 22: 453-465

Impact factor: 2.918 (99 cit.)

  1. Hoerndli F, Toigo M, Schild A, Götz J, Day P (2004) Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative PCR, Anal. Biochem. 335: 30-41

Impact factor: 2.305 (61 cit.)

 

  1. David D, Hoerndli F, Götz J (2005) Application of functional genomics to neurodegenerative disorders. Part I, Transcriptomic and proteomic technology, Prog. Neurobiol. 76: 153-168

Impact factor: 10.301 (36 cit.)

  1. Hoerndli F, David D, Götz J (2005) Application of functional genomics to neurodegenerative disorders. Part II, Application and data integration, Prog. Neurobiol. 76: 169-188

Impact factor: 10.301 (37 cit.)

  1. Götz J, Ittner LM, David DC (2005) Role of the protein tau in Alzheimer’s disease, Drug Disc. Today: Dis. Mech. 2: 395-400

Impact factor: 5.964 (2 cit.)

  1. David D, Hauptmann S, Scherping I, Schuessel K, Keil U, Dröse S, Brandt U, Müller WE, Eckert A, and Götz J (2005) Proteomic and functional analysis reveal a mitochondrial dysfunction in P301L tau transgenic mice, J. Biol. Chem. 280: 23802-23814 [selected for Faculty of 1000 Biology]

Impact factor: 4.600 (193 cit.)

  1. Pennanen L, Götz J (2005) Different tau epitopes define Aβ42-mediated tau insolubility, Biochem. Biophys. Res. Commun. 337:1097-101

Impact factor: 2.281 (27 cit.)

 

  1. Schild A, Schmidt K, Lim Y-A, Ke Y, Ittner LM, Hemmings BA, Götz J (2006) Altered levels of PP2A regulatory B/PR55 isoforms indicate role in neuronal differentiation, Int J Dev Neurosci. 24: 437-443

Impact factor: 2.918 (19 cit.)

  1. Pennanen L, Wolfer DP, Nitsch RM, Götz J (2006) Impaired reference memory and increased exploratory behavior in P301L tau transgenic mice, Genes, Brain Behav. 5:369-379

Impact factor: 3.505 (58 cit.)

  1. David DC, Ittner LM, Gehrig P, Nergenau D, Shepherd C, Halliday G, Götz J (2006) β-Amyloid treatment of two complementary P301L tau-expressing Alzheimer’s disease models reveals similar deregulated cellular processes, Proteomics 6: 6566-6577

Impact factor: 3.973 (62 cit.)

  1. Schild A, Isenmann S, Tanimoto N, Tonagel F, Seliger MW, Ittner LM, Kretz A, Ogris E, Götz J (2006) Impaired development of the Harderian gland in mutant protein phosphatase 2A transgenic mice, Mech. Dev. 123: 362-371

Impact factor: 2.958 (13 cit.)

  1. Schild A, Ittner LM, Götz J (2006) Altered phosphorylation of cytoskeletal proteins in mutant protein phosphatase 2A transgenic mice, Biochem. Biophys. Res. Commun. 343: 1171-1178

Impact factor: 2,281 (25 cit.)

  1. Götz J, Ittner LM, Schonrock N (2006) Alzheimer’s Disease and Frontotemporal Dementia – Prospects of a tailored therapy?, Med. J. Aust. 185: 381-384

Impact factor: 3.789 (18 cit.)

  1. Götz J, Ittner L, Kins S (2006) Do axonal defects in tau and APP transgenic animals model axonopathy in Alzheimer’s disease?, J. Neurochem. 98: 993-1006

Impact factor: 4.244 (95 cit.)

  1. Kulic L, Kurosinski P, Chen F, Tracy J, Mohajeri MH, Li H, Nitsch RM, Götz J (2006) Active immunization trial in Aβ42-injected P301L tau transgenic mice, Neurobiology of Disease 22: 50-56

Impact factor: 5.202 (19 cit.)

  1. Tam CW, Husmann K, Clark NC, Clark JE, Lazar Z, Ittner LM, Götz J, Douglas G, Grant AD, Sugden D, Poston L, Poston R, McFadzean I, Marber MS, Fischer JA, Born W, Brain SD (2006) Enhanced vascular responses to adrenomedullin in mice overexpressing receptor activity-modifying protein 2., Circulation Res. 98: 262-70

Impact factor: 11.089 (32 cit.)

  1. Pei J-J, An W-L, Zhou X-W, Nishimura T, Norberg J, Benedikz E, Götz J, Winblad B (2006) P70S6 kinase mediates tau phosphorylation and synthesis, FEBS Letters 580: 107-114

Impact factor: 3.341 (49 cit.)

 

  1. Burke D, Hickie I, Breakspear M, Götz J (2007) Is there good news about dementia? Possibilities for the prevention and treatment of cognitive impairment and dementia, Brit. J. Psychiatry 190: 371-372

Impact factor: 7.343 (23 cit.)

  1. Habicht G, Haupt C, Friedrich RP, Hortschansky P, Sachse C, Meinhardt J, Wieligmann K, Gellermann G, Brodhuhn M, Götz J, Grigorieff N, Halbhuber K-J, Röcken C, Horn U, Fändrich M (2007) Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils, PNAS 104: 19232-19237

Impact factor: 9.809 (149 cit.)

  1. Ittner LM, Götz J (2007) Pronuclear injection for the production of transgenic mice, Nature Protocols 2(5): 1206-1215

Impact factor: 7.782 (67 cit.)

  1. Götz J, Deters N, Doldissen A, Ke Y, Bokhari L, Wiesner A, Schonrock N, Ittner LM (2007) A decade of tau transgenic animal models and beyond, Brain Pathol., 17 (1): 91-103

Impact factor: 4.354 (99 cit.)

  1. Hoerndli F, Pelech S, Papassotiropoulos, Götz J (2007) Aβ treatment and P301L tau expression in an Alzheimer’s disease tissue culture model act synergistically to promote aberrant cell cycle re-entry, Eur. J. Neurosci. 26(1): 60-72

Impact factor: 3.669 (29 cit.)

 

  1. Eckert A, Hauptmann S, Scherping I, Rhein V, Müller-Spahn F, Götz J, Müller WE (2008) Soluble amyloid-beta leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice, Neurodeg Dis. 5: 157-9

Impact factor: 3.454 (87 cit.)

  1. Ittner LM, Schwerdtfeger K, Kunz TH, Muff R, Husmann K, Grimm C, Hafezi F, Lang KS, Kurrer MO, Götz J, Born W, Fischer JA (2008) Transgenic mice with ocular overexpression of an adrenomedullin receptor reflect human acute angle-closure glaucoma, Clinical Science, 114(1): 49-58

Impact factor: 5.629 (8 cit.)

  1. Götz J, David D, Hoerndli F, Ke YD, Schonrock N, Wiesner A, Fath T, Bokhari L, Lim Y-A, Deters N, and Ittner LM (2008) Functional Genomics dissects pathomechanisms in tauopathies: Mitosis failure and unfolded protein response, Neurodeg Dis. 5: 179-181

Impact factor: 3.454 (5 cit.)

  1. Götz J, Ittner LM, Fändrich M, Schonrock N (2008) Is tau aggregation toxic or protective – a sensible question in the absence of sensitive methods?, J Alzheimers Dis 14(4): 423-429

Impact factor: 3.612 (23 cit.)

  1. Götz J, Ittner LM (2008) Animal models of Alzheimer’s disease and frontotemporal dementia, Nature Rev Neurosci 9: 532-544 [Featured article]

Impact factor: 31.376 (369 cit.)

  1. Baur K, Rauer M, Richter K, Pagenstecher A, Götz J, Hausmann J, Staeheli, P (2008) Antiviral CD8 T cells recognize Borna disease virus antigen transgenically expressed in either neurons or astrocytes, J. Virol. 82: 3099-3108

Impact factor: 4.648 (14 cit.)

  1. Lim Y-A, Ittner LM, Lim YL, Götz J (2008) Human but not rat amylin shares neurotoxic properties with Aβ42 in long-term hippocampal and cortical cultures, FEBS Letters 582: 2188-2194 [cover image]

Impact factor: 3.341 (34 cit.)

  1. Deters N, Ittner LM, Götz J (2008) Divergent phosphorylation pattern of tau in P301L tau transgenic mice, Eur. J. Neurosci. 28: 137-147

Impact factor: 3.669 (44 cit.)

  1. Pienaar IS, Daniels WMU, Götz J (2008) Neuroproteomics as a promising tool in Parkinson’s disease research, J Neural Transm. 115: 1413-30

Impact factor: 2.871 (22 cit.)

  1. Ittner LM, Fath T, Ke Y, Bi M, van Eersel J, Li KM, Gunning P, Götz J (2008) Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia, PNAS 105: 15997-16002

Impact factor: 9.809 (109 cit.)

  1. Götz J, Ittner LM, Schonrock N, Cappai R (2008) An update on the toxicity of Aβ in Alzheimer’s disease, Neuropsych Dis and Treatm. 4: 1033-42

Impact factor: N.A. (31 cit.)

  1. Eckert A, Hauptmann S, Scherping I, Rhein V, Dröse S, Brandt U, Müller WE, Götz J (2008) Oligomeric and fibrillar species of β-amyloid (Aβ42) both impair mitochondrial function in P301L tau transgenic mice, J Mol Med 86: 1255-67 [selected for Faculty of 1000 Biology]

Impact factor: 4.739 (92 cit.)

 

  1. Fath T, Ke YD, Gunning P, Götz J, Ittner LM (2009) Primary support cultures of hippocampal and substantia nigra neurons, Nature Protocols 4: 78-85

Impact factor: 7.782 (67 cit.)

  1. Deters N, Ittner LM, Götz J (2009) Substrate-specific reduction of PP2A activity exaggerates tau pathology, Biochem. Biophys. Res. Commun. 379: 400-5

Impact factor: 2,595 (30 cit.)

  1. Götz J, Schonrock N, Vissel B, Ittner LM (2009) Alzheimer’s disease selective vulnerability and modelling in transgenic mice, J Alzheimers Dis 18: 243-51

Impact factor: 3.612 (24 cit.)

  1. Götz J, Ittner LM, Lim Y-A (2009) Common features between Diabetes mellitus and Alzheimer’s disease, Visions and Reflections, Cell Mol Life Sci. 66: 1321-5 plus Response to the comment ‘Iron, type 2 diabetes mellitus, and Alzheimer’s disease’ to our Visions and Reflections article ‘Common features between diabetes mellitus and Alzheimer’s disease’ Cell Mol Life Sci. 66: 2945

Impact factor: 5.856 (83 cit.)

  1. Götz J (2009) Tiermodelle in der Alzheimerforschung, Gehirn&Geist, Spektrum der Wissenschaften, May issue, p. 54-59

Impact factor: N.A.

  1. Ittner LM, Ke YD, Götz J (2009) Phosphorylated tau interacts with JNK interacting protein 1 (JIP1) in Alzheimer’s disease, J. Biol. Chem. 284: 20909-16

Impact factor: 4.600 (74 cit.)

  1. Van Eersel J, Bi M, Ke YD, Hodges JR, Xuereb JH, Gregory GC, Halliday GM, Götz J, Kril JJ, Ittner LM (2009) Phosphorylation of soluble tau differs in Pick’s disease and Alzheimer’s disease brains, J Neural Transm 116: 1243-51

Impact factor: 2.862 (20 cit.)

  1. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, Ozmen L, Bluethmann H, Dröse S, Brandt U, Savaskan E, Czech C, Götz J, Eckert A (2009) Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice, PNAS 106: 20057-62. [Highlighted in Nature Rev Neurosci, Jan 2010: http://www.nature.com/nrn/journal/v11/n1/pdf/nrn2777.pdf%5D

Impact factor: 9.809 (250 cit.)

  1. Götz J, Götz NN (2009) Animal models for Alzheimer’s disease and frontotemporal dementia: a perspective, ASN Neuro 1(4). pii: e00019

Impact factor: 4.436 (24 cit.)

  1. Ke YD, Delerue F, Gladbach A, Götz J, Ittner LM (2009) Experimental diabetes mellitus exacerbates the tau pathology in a transgenic mouse model of Alzheimer’s disease, PLoS ONE 4 (11): e7917 (Oct 29, 2009)

Impact factor: 3.534 (99 cit.)

 

  1. Götz J, Gladbach A, Pennanen L, van Eersel J, Schild A, David D, Ittner LM (2010) Animal models reveal role for tau phosphorylation in human disease,

BBA-Mol Basis Dis, Special issue on ‘Mouse Models of Human Neurological Disorders’ (BBADIS-09-30), 1802(10):860-71. Epub 2009 Sep 12

Impact factor: 5.089 (39 cit.)

  1. Götz J, Lim Y-A, Ke YD, Eckert A, and Ittner LM (2010) Dissecting toxicity of tau and β-amyloid, Neurodeg Dis. 7:10-12

Impact factor: 3.791 (13 cit.)

  1. Lim Y-A, Rhein V, Baysang G, Meier F, Poljak A, Raftery M, Ittner LM, Guilhaus M, Eckert A, Götz J (2010) Aβ and human amylin share a common toxicity pathway via mitochondrial dysfunction, Proteomics 10: 1621-33

Impact factor: 3.973 (62 cit.)

  1. Krupka N, Strappe P, Götz J, Ittner LM (2010) Gateway compatible lentiviral transfer vectors for ubiquitin promoter driven expression of fluorescent fusion proteins, Plasmid 63: 155-60

Impact factor: 1.760 (9 cit.)

  1. Eckert A, Rhein V, Schulz KL, Götz J (2010) Convergence of amyloid-β and tau pathologies on mitochondria in vivo, Mol Neurobiol 41: 107-14

Impact factor: 6.068 (67 cit.)

  1. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J (2010) Dendritic function of tau mediates amyloid- β toxicity in Alzheimer’s disease mouse models, Cell 142: 387-397 [discussed in a Perspectives article: Haass C & Mandelkow E (2010) Fyn-Tau-amyloid: a toxic triad. Cell 142: 356-8] [Highlighted in Nature Rev Neurosci, Sep 2010] [Highlighted in Nature Biotechnology, Sep 2010][Selected for Faculty of 1000 Biology]

Impact factor: 33.116 (521 cit.)

  1. Schonrock N, Ke YD, Humphreys D, Staufenbiel M, Ittner LM, Preiss T, Götz J (2010) Neuronal microRNA deregulation in response to Alzheimer’s disease amyloid-β, PLoS One 5(6): e11070. doi:10.1371/journal.pone.0011070

Impact factor: 3.534 (97 cit.)

  1. Köhler C, Bista, P, Götz J, Schröder H (2010) Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy, Brain Res 1347: 111-24

Impact factor 2.828 (4 cit.)

  1. van Eersel, J, Ke YD, Liu X, Kril J, Götz J, Ittner LM (2010) Sodium selenate treatment mitigates tau pathology in Alzheimer’s disease models, PNAS 107: 13888-93

Impact factor: 9.809 (96 cit.)

  1. Pienaar IS, Götz J, Feany M (2010) Parkinson’s disease: insights from non-traditional model organisms, Prog. Neurobiol. 92: 558-71

Impact factor: 10.301 (42 cit.)

 

  1. Hundelt M, Fath T, Selle K, Oesterwind K, Jordan J, Schultz C, Götz J, von Engelhardt J, Monyer H, Lewejohann L, Sachser N, Bakota L, Brandt R (2011) Altered phosphorylation but no neurodegeneration in a mouse model of tau hyperphosphorylation, Neurobiol Aging 32:991-1006 (Epub 2009 Aug 5)

Impact factor: 4.853 (16 cit.)

  1. Ittner LM, Götz J (2011) Amyloid-β and tau–a toxic pas de deux in Alzheimer’s disease, Nature Reviews Neurosci 12: 65-72 [reprinted in Nature 475:S23-S28][translated into German for: Spektrum der Wissenschaft]

Impact factor: 31.376 (380 cit.)

  1. Attems J, Ittner A, Jellinger K, Nitsch RM, Maj M, Wagner L, Götz J, Heikenwalder J (2011), Reduced secretagogin expression in the hippocampus of P301L tau transgenic mice, J Neural Transm 118:737-45

Impact factor: 2.862 (10 cit.)

  1. Louis JV, Martens E, Borghgraef P, Lambrecht C, Longin S, Zwaenepoel K, Pijnenborg R, Landrieu I, Lippens G, Ledermann B, Götz J, Van Leuven F, Goris J, Janssens V (2011) Mice lacking phosphatase PP2A subunit PR61/B’δ (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3β, PNAS 108:6957-62

Impact factor: 9.809 (35 cit.)

  1. Ittner A, Ke YD, van Eersel J, Gladbach A, Götz J, Ittner LM (2011), Brief update on different roles of tau in neurodegeneration, IUBMB Life 63:495-502

Impact factor: 2.755 (24 cit.)

  1. Götz J, Eckert A, Matamales M, Ittner LM, Liu X (2011), Modes of Aβ toxicity in Alzheimer’s disease, Cell Mol Life Sci. 68:3359-75

Impact factor: 5.856 (55 cit.)

  1. Eckert A, Schmitt K, Götz J (2011), Mitochondrial dysfunction – the beginning of the end in Alzheimer’s disease? Separate and synergistic modes of tau and amyloid-beta toxicity, Alzheimer’s Research & Therapy 3:15

Impact factor: 3.500 (40 cit.)

  1. Van Eersel J, Ke YD, Gladbach A, Bi M, Götz J, Kril JJ, Ittner LM (2011) Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons, PLoS ONE 6 (7): e22850 (Epub Jul 29, 2011)

Impact factor: 3.534 (31 cit.)

  1. Götz J, Ittner A, Ittner LM (2011), Tau-targeted treatment strategies in Alzheimer’s disease, Brit J Pharmacol. 165(5): 1246-59

Impact factor: 4.990 (48 cit.)

  1. Bi M, Ittner A, Ke Y, Götz J, Ittner LM (2011) Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic pR5 mice, PLoS ONE, 6(12):e26860

Impact factor: 3.534 (69 cit.)

  1. Liu X, Dobbie M, Tunningley R, Whittle B, Zhang Y, Ittner LM, Götz J (2011) ENU mutagenesis screen to identify modifiers of a motor phenotype in tau mutant mice, J Biomed Biotechnol 130947 (doi: 10.1155/2011/130947)

Impact factor: 2.706 (5 cit.)

  1. Lim Y-A, Grimm A, Giese M, Mensah-Nyagan AG, Villafranca JE, Ittner LM, Eckert A, Götz J (2011) Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol, PLoS ONE 6(12):e28887

Impact factor: 3.534 (17 cit.)

  1. Götz J, Matamales M, Götz NN, Ittner LM, Eckert A (2011) Alzheimer’s disease models and functional genomics – How many needles are there in the haystack?, IN:

Topic Title: ‘From structural to molecular systems biology: experimental and computational approaches to unravel mechanisms of kinase activity regulation in cancer and neurodegeneration’, Front Physiol., doi: 10.3389/fphys.2012.00320 Epub 2012 Aug 8.

Impact factor: N.A.

(7 cit.)

 

  1. Schonrock N, Matamales M, Ittner LM, Götz J (2012) miRNA networks surrounding APP and amyloid-β metabolism – Implications for Alzheimer’s disease, Exp Neurol 235(2): 447-54

Impact factor: 4.617 (35 cit.)

  1. Schonrock, N, Humphreys D, Preiss T, Götz J (2012) Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-β, J Mol Neurosci 46: 324-35

Impact factor: 2.757 (40 cit.)

  1. Schmitt K, Grimm A, Kazmierczak A, Strosznajder J, Götz J, Eckert A (2012) Insights into mitochondrial dysfunction: aging, amyloid-beta and tau – a deleterious trio, Antioxidants & Redox Signaling (ARS) 16 (12): 1456-66

Impact Factor: 7.667 (42 cit.)

  1. Khurana V, Merlo P, DuBoff B, Fulga TA, Sharp KA, Campbell S, Götz J, Feany MB (2012) A neuroprotectice role for the DNA damage checkpoint in tauopathy, Aging Cell 11 (2): 360-2

Impact factor: 5.939 (11 cit.)

  1. Ke Y, Dramiga Y, Schütz U, Ittner LM, Schröder H, Götz J (2012) Tau-mediated nuclear depletion of SFPQ in Alzheimer’s and Pick’s disease, PLoS ONE 7(4):e35678 [selected for Faculty of 1000 Biology]

Impact factor: 3.534 (25 cit.)

  1. Lim Y-A, Giese M, Shepherd C, Halliday G, Kobayashi M, Takamatsu K, Staufenbiel M, Eckert A, Götz J (2012) Role of hippocalcin in mediating amyloid-beta toxicity, BBA-Mol Basis Dis, 1822 (8): 1247-57

Impact factor: 5.089 (5 cit.)

  1. Grimm A, Lim Y-A, Mensah-Nyagan AG, Götz J, Eckert A (2012) Alzheimer’s disease, oestrogen and mitochondria: An ambiguous relationship, Mol Neurobiol 46 (1): 151-60

Impact factor: 5.286 (19 cit.)

  1. DuBoff B, Götz J, Feany M (2012) Tau promotes neurodegeneration via DRP1 mislocalization in vivo, Neuron 75: 618-32 [Highlighted by Cell leading Edge, Cell 151, 7-8, Sep 28, 2012]

Impact factor: 15.982 (69 cit.)

  1. Schonrock N, Götz J (2012) Decoding the non-coding RNAs in Alzheimer’s disease, Cell Mol Life Sci 69: 3543-59

Impact factor: 5.856 (26 cit.)

 

  1. Köhler C, Dinekov M, Götz J (2013) Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice, Neurobiol Aging 34: 1369-79

Impact factor: 4.853 (6 cit.)

  1. Morcinek K, Köhler C, Götz J, Schröder H (2013) Pattern of tau hyperphosphorylation and neurotransmitter markers in the brainstem of senescent tau filament forming transgenic mice, Brain Res 1497: 73-84

Impact factor: 2.728

  1. Nilsen LH, Rae C, Ittner LM, Götz J, Sonnewald U (2013) Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation, J Cereb Blood Flow Metab. 33: 684-91

Impact factor 5.339 (10 cit.)

  1. Chew YL, Fan X, Götz J, Nicholas HR (2013) Protein with tau-like repeats (PTL1) regulates neuronal integrity and lifespan in C. elegans, J Cell Sci 126: 2079-91

Impact factor: 5.325 (14 cit.)

  1. DuBoff B, Feany M, Götz J (2013) Why size matters – Balancing mitochondrial dynamics in Alzheimer’s disease, Trends in Neurosciences 36: 325-335

Impact factor: 12.902 (31 cit.)

  1. Delerue F, Sjollema G, Whittle B, Krüger S, Andrews D, Götz J (2013) Single nucleotide variants (SNVs) define senescence-accelerated SAMP8 mice, a model of a geriatric condition, J Alzheimers Dis 36: 325-35

Impact factor: 3.612 (4 cit.)

  1. Liu C, Götz J (2013) Inge Iqbal memorial: How it all started – tau and protein phosphatase 2A, J Alzheimers Dis 37: 483-94

Impact factor: 3.612 (5 cit.)

  1. Götz J, Xia D, Leinenga G, Chew YL, Nicholas H (2013) What renders tau toxic, IN: Topic title: Frontiers in Neurodegeneration, Research Topic: Tau oligomers, Frontiers Neurol, 4: 72, doi: 10.3389/fneur.2013.00072

Impact factor: N.A. (18 cit.)

  1. Chew YL, Fan X, Götz J, Nicholas HR (2013) Aging in the nervous system of Caenorhabditis elegans, Commun Integr Biol. 6:5, e25288

Impact factor: N.A.

  1. Götz J, Lim Y-A, Eckert A (2013) Lessons from two prevalent amyloidoses – what amylin and Ab have in common, IN: Research topic: ‘Alzheimer’s disease and Type 2 Diabetes: Dissecting toxicity in conformational diseases’, Frontiers in Aging Neuroscience, 5: 38, doi: 10.3389/fnagi.2013.00038

Impact factor: 2.843 (5 cit.)

  1. Eckert A, Nisbet R, Grimm A, Götz J (2013) March separate, strike together – Role of phosphorylated tau in mitochondrial dysfunction in Alzheimer’s disease, Biochim Biophys Acta, in press (acc. Sep 7, 2013)

Impact factor 5.211 (10 cit.)

  1. Liu C, Götz J (2013) Profiling murine tau with 0N, 1N and 2N isoform-specific antibodies in brain and peripheral organs reveals distinct subcellular localization, with the 1N isoform being enriched in the nucleus, PLOS ONE 8 (12): e84849

Impact factor: 3.534 (6 cit.)

 

  1. Liang V, Ullrich M, Lam H, Chew YL, Banister S, Song X, Zaw T, Kassiou M, Götz J*, Nicholas HR* (2014) Altered proteostasis in aging and heat shock response in C. elegans revealed by analysis of the global and de novo synthesised proteome, Cell Mol Life Sci. 71: 3339-61

(*equal contribution)

Impact factor: 6.265 (7 cit.)

  1. Lu J, Li T, He R, Bartlett PF, Götz J (2014) Visualizing the microtubule-associated protein tau in the nucleus, Sci China Life Sci., Special Issue: “From Brain Function to Therapy” 57: 422-31

Impact factor: 2.024 (3 cit.)

  1. Chen J, Mengru S, Wang X, Lu J, Wei Y, Tan Y, Liu Y, Götz J, He R, Hua Q (2014) The herbal compound Geniposide rescues formaldehyde-induced apoptosis in N2a neuroblastoma cells, Sci China Life Sci., Special Issue: “From Brain Function to Therapy” 57: 412-21

Impact factor: 2.024 (4 cit.)

  1. Xia D, Götz J (2014) Premature lethality, hyperactivity and aberrant phosphorylation in transgenic mice expressing a constitutively active form of Fyn, Frontiers Mol Neurosci, Research Topic: ‘Kinase dysregulation in Alzheimer’s disease’ 7:40. doi: 10.3389/fnmol.2014.00040. eCollection 2014.

Impact factor: N.A. (1 cit.)

  1. Chew YL, Fan X, Götz J, Nicholas HR (2014) Regulation of age-related structural integrity in neurons by protein with tau-like repeats (PTL-1) is cell autonomous, Scientific Reports 4: 5185

Impact factor: 5.078 (2 cit.)

  1. Ullrich M, Liang V, Chew YL, Banister S, Song X, Zhaw T, Kam H, Berger S, Kassiou M, Nicholas HR*, Götz J* (2014) Bio-orthogonal labelling as a tool to identify newly synthesized proteins in the roundworm C. elegans, Nature Protocols 9: 2237-55 (*equal contribution)

Impact factor: 7.782 (1 cit.)

  1. Köhler C, Dinekov M, Götz J (2014) Granulovacuolar degeneration and unfolded protein response in mouse models of tauopathy and Aβ amyloidosis, Neurobiology of Disease 71:169-79

Impact factor: 5.202 (1 cit.)

 

  1. Chew Y, Götz J, Nicholas HR (2015) Neuronal protein with tau-like repeats PTL-1 regulates intestinal SKN-1 relocalisation in response to oxidative stress, Aging Cell 14: 148-51

Impact factor: 5.705

  1. Frost B, Götz J, Feany M (2015) Connecting the dots between tau dysfunction and neurodegeneration, Trends Cell Biol 25: 46-53

Impact factor 12.314 (9 cit.)

  1. Ittner A, Bertz J, Götz J, Ittner LM (2015) Tau-targeted passive immunization modulates aspects of pathology in Tau transgenic mice, J Neurochem 132: 135-45

Impact factor 3.973 (4 cit.)

  1. Baker S, Götz J (2015) What can we learn about cerebral multi-morbidity from animal models? (in: Series on Cerebral Multimorbidity), Alzheimer’s Research & Therapy 7:11

Impact factor: 3.500

  1. Nisbet R, Polanco JC, Ittner LM, Götz J (2015) Tau aggregation and its interplay with amyloid-beta, Acta Neuropathologica 129:207-20

Impact factor: 9.777 (4 cit.)

  1. Xia D, Li C, Götz J (2015) Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines, BBA-Mol Basis Dis. (Biochim Biophys Acta) 1852: 913-924

Impact factor: 5.089

  1. Cummins NT, Götz J (2015) Dementia and neurodegeneration – Role of mitochondria in Alzheimer’s disease, Austr. Biochem., in press (acc. Feb 6, 2015)

Impact factor: N.A.

  1. Leinenga G, Götz J (2015) Scanning ultrasound efficiently removes amyloid-β and restores memory in an Alzheimer’s disease mouse model, Science Transl Med 11: 276ra33

Impact factor: 14.414 [Cover image] [Highlighted in Science 347: 1186-87, 2015] [Highlighted in Nature Rev Neurol] (1 cit.)

  1. Burrell JR, Halliday G, Kril JJ, Ittner L, Götz J, Kiernan MC, Hodges JR (2015) The frontotemporal dementia-motor neuron disease continuum, Lancet, in press (acc. March 31, 2015)

Impact factor: 39.207

  1. Ittner LM, Halliday GM, Kril JJ, Götz J, Hodges JR, Kiernan MC (2015) FTD and ALS – translating mouse studies into clinical trials, Nature Rev Neurol, in press (acc. April 11, 2015)

Impact factor: 14.103

 

(b) Book chapters and other contributions

 

  1. Goedert M, Spillantini MG, Jakes R, Crowther RA, Cohen P, Vanmechelen E, Probst A, Götz J, Bürki K (1995) Molecular dissection of the paired helical filament. In: Recent Advances in Alzheimer’s Disease and Related Disorders (K.Iqbal, J.Mortimer, B.Winblad & H.Wisniewski,eds). Wiley and Sons, chapter 54: 493-502
  2. Götz J (2002) Die Alzheimer’sche Krankheit: Wechselwirkung zwischen Tau und β-Amyloid, Festschrift aus Anlass der Verleihung des Georg Friedrich Götz-Preises 2002, p. 1-17
  3. Chen F, Ferrari A, Schild A, Kurosinski P, David D, Hoerndli F, Pennanen L, Kins S, van Dorpe J, Nitsch RM, Götz J (2003) Amyloid-induced neurofibrillary tangle formation. In: Alzheimer’s disease and related disorders: Research advances (editors: K. Iqbal, B. Winblad; Ana Aslan International Foundation), p. 343-354 (chapter 30)
  4. Götz J, Chen F (2006) Glyoxalase I and Alzheimer’s disease (chapter 10). In: Research Progress in Alzheimer’s Disease and Dementia (editor: M.-K. Sun; Nova Science Publishers, Inc., New York), ISBN 1-59454-949-4
  5. Götz J, David DC, Ittner L (2007) Impact of β-amyloid on the tau pathology in tau transgenic mouse and tissue culture models (chapter 12/16). In: Celebrating a Century of Research. Abeta Peptide and Alzheimer’s Disease (editors: Colin C. Barrow and David H. Small, Springer-Verlag London Ltd.), ISBN-13: 978-1-85233-961-6
  6. Götz J, Ittner LM, Götz NN, Lam H, Nicholas H (2011) RSC (The Royal Society of Chemistry) Drug Discovery Series, Animal Models for Neurodegenerative Disease, ‘Invertebrate and vertebrate models of tauopathies’, Edited by Jesús Avila, Jose J Lucas and Félix Hernández (ISBN-10: 1849731845) 6: 69-85
  7. Götz J, Schonrock N, Vissel B, Ittner LM (2010) Alzheimer’s disease selective vulnerability and modelling in transgenic mice, in J Alzheimers Dis Handbook ‘Animal Models of Alzheimer’s Disease’
  8. Götz J, Büttner S (2011) Stem cell therapy in Alzheimer’s disease models: neurogenesis versus trophic support, in: Frontiers in pluripotent stem cells research and therapeutic potentials. Chapter 15, Bench-to-Bedside, Ed. K Sidhu (Bentham Publishers)

 

(c) Patents

 

  1. WO 03/017918 A2 (PCT/EP02/09491), US 07550648: A method of inducing the formation of neurofibrillary tangles in transgenic animals (J. Götz, R. Nitsch, F. Chen)
  2. WO 2004/017072 (PCT/EP2003/008983): A cellular assay system for neurofibrillary tangle formation (J. Götz, R. Nitsch, A. Ferrari)
  3. WO/2009/143556 (PCT/AU2009/000608): Treatments for excitotoxicity and Abeta-mediated toxicity and age-associated neuronal dysfunction (J. Götz, L. Ittner)
  4. APPA2009904998 (PCT), Cell culture device and method (L. Ittner, T. Fath, J. Götz, Y. Ke)
  5. US Patent 20,150,017,657, ASSAY AND METHOD FOR IDENTIFYING COMPOUNDS THAT INHIBIT EXCITOTOXIC SIGNALS (L.M. Ittner, J. Götz)
  6. Provisional patent of SUSing approach: Neurodegenerative disease treatment, Application number: 2014902366 (June 20, 2014) (Götz J, Leinenga G)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s